Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)

NCT00078403 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

333

Enrollment

NIH

Sponsor class

Conditions

HIV Infections
Hepatitis C
Liver Disease

Interventions

DRUG: Peginterferon alfa-2a
DRUG: Ribavirin

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)